154 related articles for article (PubMed ID: 8976817)
1. WR-1065, the active metabolite of amifostine (Ethyol), does not inhibit the cytotoxic effects of a broad range of standard anticancer drugs against human ovarian and breast cancer cells.
Alberts DS; Speicher LA; Krutzsch M; Wymer J; Capizzi RL; Conlon J; Barrett A; Aickin M
Eur J Cancer; 1996; 32A Suppl 4():S17-20. PubMed ID: 8976817
[TBL] [Abstract][Full Text] [Related]
2. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
3. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC).
Khodarev NN; Kataoka Y; Murley JS; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):553-63. PubMed ID: 15380592
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotection of rat heart myocytes with amifostine (Ethyol) and its free thiol, WR-1065, in vitro.
Dorr RT; Lagel K; McLean S
Eur J Cancer; 1996; 32A Suppl 4():S21-5. PubMed ID: 8976818
[TBL] [Abstract][Full Text] [Related]
5. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
[TBL] [Abstract][Full Text] [Related]
6. Delayed radioprotection by NFkappaB-mediated induction of Sod2 (MnSOD) in SA-NH tumor cells after exposure to clinically used thiol-containing drugs.
Murley JS; Kataoka Y; Cao D; Li JJ; Oberley LW; Grdina DJ
Radiat Res; 2004 Nov; 162(5):536-46. PubMed ID: 15624308
[TBL] [Abstract][Full Text] [Related]
7. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
8. Amifostine protects normal tissues from paclitaxel toxicity while cytotoxicity against tumour cells is maintained.
Taylor CW; Wang LM; List AF; Fernandes D; Paine-Murrieta GD; Johnson CS; Capizzi RL
Eur J Cancer; 1997 Sep; 33(10):1693-8. PubMed ID: 9389935
[TBL] [Abstract][Full Text] [Related]
9. In vitro antioxidant properties of amifostine (WR-2721, Ethyol).
Marzatico F; Porta C; Moroni M; Bertorelli L; Borasio E; Finotti N; Pansarasa O; Castagna L
Cancer Chemother Pharmacol; 2000; 45(2):172-6. PubMed ID: 10663633
[TBL] [Abstract][Full Text] [Related]
10. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
11. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
Michieli M; Michelutti A; Damiani D; Ermacora A; Masolini P; Stocchi R; Russo D
Leuk Lymphoma; 2001 Aug; 42(4):721-9. PubMed ID: 11697502
[TBL] [Abstract][Full Text] [Related]
12. Cytoprotection by WR-1065, the active form of amifostine, is independent of p53 status in human malignant glioma cell lines.
Kataoka Y; Murley JS; Patel R; Grdina DJ
Int J Radiat Biol; 2000 May; 76(5):633-9. PubMed ID: 10866285
[TBL] [Abstract][Full Text] [Related]
13. Disposition of WR-1065 in the liver of tumor-bearing rats following regional vs systemic administration of amifostine.
Levi M; DeRemer SJ; Dou C; Ensminger WD; Smith DE
Biopharm Drug Dispos; 2004 Jan; 25(1):27-35. PubMed ID: 14716750
[TBL] [Abstract][Full Text] [Related]
14. WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.
Dziegielewski J; Baulch JE; Goetz W; Coleman MC; Spitz DR; Murley JS; Grdina DJ; Morgan WF
Free Radic Biol Med; 2008 Dec; 45(12):1674-81. PubMed ID: 18845240
[TBL] [Abstract][Full Text] [Related]
15. Tissue levels of WR-1065, the active metabolite of amifostine (Ethyol), are equivalent following intravenous or subcutaneous administration in cynomolgus monkeys.
Bachy CM; Fazenbaker CA; Kifle G; McCarthy MP; Cassatt DR
Oncology; 2004; 67(3-4):187-93. PubMed ID: 15557777
[TBL] [Abstract][Full Text] [Related]
16. Activation of the nuclear transcription factor kappaB (NFkappaB) and differential gene expression in U87 glioma cells after exposure to the cytoprotector amifostine.
Kataoka Y; Murley JS; Khodarev NN; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):180-9. PubMed ID: 12007958
[TBL] [Abstract][Full Text] [Related]
17. Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug ethyol (WR-2721), protect DNA against fast neutron-induced strand breakage.
Savoye C; Swenberg C; Hugot S; Sy D; Sabattier R; Charlier M; Spotheim-Maurizot M
Int J Radiat Biol; 1997 Feb; 71(2):193-202. PubMed ID: 9120355
[TBL] [Abstract][Full Text] [Related]
18. Chemoprotection in anticancer therapy: the emerging role of amifostine (WR-2721).
Kurbacher CM; Mallmann PK
Anticancer Res; 1998; 18(3C):2203-10. PubMed ID: 9703784
[TBL] [Abstract][Full Text] [Related]
19. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Fulda S; Fichtner I; Hero B; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
